Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar06 Água potável e saneamento
13 Ação contra a mudança global do clima
15 Vida terrestre
Collections
- CDTS - Artigos de Periódicos [482]
- IOC - Artigos de Periódicos [12987]
Metadata
Show full item record
EPOXY-α-LAPACHONE IN NANOSYSTEM: A PROTOTYPE DRUG FOR LEISHMANIASIS ASSESSED IN THE BINOMIAL BALB/C – LEISHMANIA (LEISHMANIA) AMAZONENSIS
Combination therapy
Epoxy-α-lapachone
Microemulsion
Meglumine antimoniate
Author
Affilliation
Abstract
This perspective presents and supports arguments for a new formulation of epoxy-α-lapachone loaded microemulsion (ELAP-ME), a nanosystem, as a prototype drug for the treatment of leishmaniasis. The benefits of ELAP as a multitarget compound, with properties that affect key physiological pathways of Leishmania spp. are discussed. ELAP-ME demonstrated efficacy in murine infection models, particularly with the binomial BALB/c-Leishmania (Leishmania) amazonensis. Furthermore, it is proposed that the technological maturity of ELAP-ME be classified as Technology Readiness Level 4 (TLR 4) within the context of innovative drugs for American Cutaneous Leishmaniasis (ACL).
Keywords
Cutaneous leishmaniasis treatmentCombination therapy
Epoxy-α-lapachone
Microemulsion
Meglumine antimoniate
Share